NHS Offers CAR T-cell Therapy to Lupus Patients in Groundbreaking Trial
Key Insights
Three patients in the UK receive CAR T-cell therapy on the NHS in a trial offering potential remission for severe lupus (search), a disease affecting 70,000 in the UK.
The therapy genetically modifies immune cells to target and attack cells driving lupus (search) inflammation, providing a possible cure where only immunosuppression was available.
Katie Tinkler, a lupus (search) patient for 30 years, expresses hope that the trial's results will offer an endpoint for those with autoimmune diseases, improving their quality of life.
Three patients in the UK have received CAR T-cell therapy through the NHS in a groundbreaking trial that offers a potential remission for severe lupus (search). This marks a significant advancement in treating the autoimmune disease, which affects approximately 70,000 individuals in the UK. The therapy, administered at University College London Hospitals NHS Foundation Trust (UCLH), modifies cells to enable the body’s immune system to recognize and attack cells driving lupus inflammation.
Patient Perspective
Katie Tinkler, a 50-year-old lupus (search) patient from Guildford, shared her experience with the PA news agency. Diagnosed at 20, Tinkler has endured extreme joint pain, fatigue, antiphospholipid syndrome, focal myositis, and kidney disease. "I started to get extreme joint pain and, in the first few years, that was my main symptom – like excruciating," she said. Her treatment has included steroids and immunosuppressants (search), but her health has been declining. Tinkler expressed her excitement about the trial, stating, "Up until now, there’s never been anything for lupus that is a possible cure... If this works, it’s life-changing."
Mechanism of CAR T-cell Therapy
CAR T-cell therapy involves genetically modifying a patient's own T cells to target specific cells within their body. In the context of lupus (search), these modified T cells are engineered to recognize and eliminate the immune cells responsible for causing inflammation and tissue damage. This targeted approach aims to reset the immune system, potentially leading to long-term remission without the need for continuous immunosuppression.
Hope for Autoimmune Diseases
Tinkler hopes the trial will offer hope to others with autoimmune diseases. "There’s so many autoimmune diseases out there... so I hope that the results from this trial come out and it gives people the hope that everybody who has an autoimmune disease will be able to have an end point," she said. She added that until now, treatment has been limited to immunosuppression, which has its own issues. The trial represents a significant step towards finding a potential cure and improving the quality of life for those affected by lupus (search) and other autoimmune conditions.